Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates MannKind has shifted the research and development (R&D) resources allotted for its lung diseases pipeline to help fight respiratory viral infections, including Covid-19.
The company partnered with Immix Biopharma to formulate a dry powder of a compound to treat acute respiratory distress syndrome related to the novel coronavirus infection.
Initially, MannKind aims to rapidly create prototype powders. The company is also exploring other collaborations. The company’s Technosphere is a dry-powder formulation technology that enables delivery of medication to the lungs.